UNSPSC 51111603: Floxuridine

This classification denotes a pyrimidine antagonist with the molecular formula C9H11FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 039LU44I5M, chemically known as uridine, 2-deoxy-5-fluoro- but generally known as floxuridine, which bears US NIH Compound Identifier 3363. European Medicines Agency schedules Floxuridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07659MIG. The term FLOXURIDINE is an International Non-Proprietary Name.

UNSPSC 51111603 Floxuridine, a Commodity code, covers pharmaceutical procurement activity in state and local health agencies. The recent opportunity record shows minimal direct solicitation for this specific active pharmaceutical ingredient; instead, state health agencies are pursuing broader pharmacy benefit and direct-to-manufacturer contracting strategies that may encompass floxuridine and other specialty pharmaceuticals as components of larger procurement initiatives rather than standalone line items.

The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI seeks vendor experience with direct contracts for self-insured employers and health plans, negotiated net pricing models without rebates, and value-based or outcomes-based agreements. This exploratory mechanism indicates that state health agencies are restructuring pharmacy benefit procurement to bypass traditional pharmacy benefit managers and group purchasing organizations, a shift that will likely shape how specialty drugs such as floxuridine flow through state procurement channels going forward. The RFI documentation does not specify award values, budget ranges, set-aside designations, or a formal evaluation timeline, as it functions as a foundational research phase before issuing a formal RFP. No other recent state or local opportunities appear in the record under this Commodity code, suggesting that floxuridine procurement at the state and local level remains embedded in broader pharmacy benefit contracts rather than generating standalone solicitations.